Table 2

Most common AEs during the treatment period

Phase 1, n = 13Phase 2, n = 20
Patients with at least 1 AE (all grades), n (%) 13 (100) 20 (100) 
 IRR* 13 (100) 19 (95) 
  Hypotension 10 (77) 12 (60) 
  Pyrexia 8 (62) 13 (65) 
  Chills 7 (54) 6 (30) 
  Vomiting 6 (46) 11 (55) 
 Neutropenia 7 (54) 4 (20) 
 Thrombocytopenia 4 (31) 3 (15) 
 Pyrexia 3 (23) 4 (20) 
 Lymphopenia 4 (31) 2 (10) 
 Anemia 1 (8) 5 (25) 
 Febrile neutropenia 1 (8) 2 (10) 
Patients with at least 1 AE (grade 3), n (%) 8 (62) 13 (65) 
 IRR 2 (15) 5 (25) 
 Neutropenia 2 (15) 1 (5) 
 Febrile neutropenia 0 (0) 0 (0) 
 Lymphopenia 2 (15) 2 (10) 
 Thrombocytopenia 2 (15) 0 (0) 
 Leukopenia 2 (15) 1 (5) 
 Anemia 0 (0) 2 (10) 
Patients with at least 1 AE (grade 4), n (%) 6 (46) 7 (35) 
 Neutropenia 5 (38) 3 (15) 
 Febrile neutropenia 1 (8) 1 (5) 
 Thrombocytopenia 0 (0) 3 (15) 
Phase 1, n = 13Phase 2, n = 20
Patients with at least 1 AE (all grades), n (%) 13 (100) 20 (100) 
 IRR* 13 (100) 19 (95) 
  Hypotension 10 (77) 12 (60) 
  Pyrexia 8 (62) 13 (65) 
  Chills 7 (54) 6 (30) 
  Vomiting 6 (46) 11 (55) 
 Neutropenia 7 (54) 4 (20) 
 Thrombocytopenia 4 (31) 3 (15) 
 Pyrexia 3 (23) 4 (20) 
 Lymphopenia 4 (31) 2 (10) 
 Anemia 1 (8) 5 (25) 
 Febrile neutropenia 1 (8) 2 (10) 
Patients with at least 1 AE (grade 3), n (%) 8 (62) 13 (65) 
 IRR 2 (15) 5 (25) 
 Neutropenia 2 (15) 1 (5) 
 Febrile neutropenia 0 (0) 0 (0) 
 Lymphopenia 2 (15) 2 (10) 
 Thrombocytopenia 2 (15) 0 (0) 
 Leukopenia 2 (15) 1 (5) 
 Anemia 0 (0) 2 (10) 
Patients with at least 1 AE (grade 4), n (%) 6 (46) 7 (35) 
 Neutropenia 5 (38) 3 (15) 
 Febrile neutropenia 1 (8) 1 (5) 
 Thrombocytopenia 0 (0) 3 (15) 
*

Events occurring during or within 24 hours of an infusion for which there was a reasonable suspected causal relationship with that infusion.

or Create an Account

Close Modal
Close Modal